UK markets closed

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.07+0.14 (+1.37%)
At close: 06:10PM BST
Full screen
Loading interactive chart…
  • Reuters

    Valneva cuts full-year outlook on lower COVID-19 vaccine sales

    The European Commission in July slashed its order for VLA2001 to just 1.25 million doses from a previously targeted 60 million, pointing to European countries being well supplied with other vaccines and a slowdown in vaccination programmes. In February, Valneva had said it expected 350-500 million euros in COVID-19 vaccine sales. In the six months to June, the shot's sales brought in 3.8 million euros and the firm recognised writedowns of 100.6 million linked to the production inventory it bought to meet the initial purchase agreement with the European Commission, and subsequent halt of production.

  • Globe Newswire

    Valneva Reports H1 2022 Results and Provides Corporate Updates

    Excellent progress on late-stage clinical programs Lyme Disease Vaccine Candidate VLA15 Phase 3 study initiated in August 20221Further positive Phase 2 results reported, including first pediatric data2 Single-Shot Chikungunya Vaccine Candidate VLA1553 Initiation of rolling submission for Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) imminentFinal positive pivotal Phase 3 results reported3Final positive lot-to-lot consistency Phase 3 results reported4 Four m

  • Globe Newswire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. New York & Saint-Herblain (France), August 8, 2022 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate,